نتایج جستجو برای: جهش jak2

تعداد نتایج: 7772  

2013
Sung O. Park Heather L. Wamsley Kyungmi Bae Zhongbo Hu Xiaomiao Li Se-woon Choe William B. Slayton S. Paul Oh Kay-Uwe Wagner Peter P. Sayeski

Germline deletion of Jak2 in mice results in embryonic lethality at E12.5 due to impaired hematopoiesis. However, the role that Jak2 might play in late gestation and postnatal life is unknown. To understand this, we utilized a conditional knockout approach that allowed for the deletion of Jak2 at various stages of prenatal and postnatal life. Specifically, Jak2 was deleted beginning at either m...

A Ghavamzadeh, A Zaghal, B Bahar, B Chahardouli, H Dargahi, K Alimoghaddam, N Einollahi, P Karimzadeh, SA Mousavi, SH Ghaffari,

Abstract Objective JAK2 is a non-receptor tyrosine kinase that plays a major role in myeloid disorders. JAK2V617F mutation is characterized by a G to T transverse at nucleotide 1849 in exon 12 of the JAK2 gene, located on the chromosome 9p, leading to a substitution of valine to phenylalanine at amino acid position 617 in the JAK2 protein. Methods In this study we evaluated RNA from 89 pati...

Journal: :Blood 2012
Mamta Gupta Jing Jing Han Mary Stenson Matthew Maurer Linda Wellik Guangzhen Hu Steve Ziesmer Ahmet Dogan Thomas E Witzig

Cytokines are deregulated in cancers and can contribute to tumor growth. In patients with diffuse large-cell lymphoma (DLBCL), we observed higher levels of JAK/STAT pathway-related serum cytokines (ie, IL-6, IL-10, epidermal growth factor, and IL-2) compared with controls. Of these, only IL-10 activated the JAK2 pathway in lymphoma cells in vitro. Patients with high serum IL-10 had shorter even...

Journal: :American journal of clinical pathology 2011
Jennifer Dunlap Katalin Kelemen Nicky Leeborg Rita Braziel Susan Olson Richard Press James Huang Ken Gatter Marc Loriaux Guang Fan

Myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms are heterogeneous disorders. JAK2 mutation testing and karyotyping are routinely used for diagnosis but have not been incorporated into risk stratification in Philadelphia chromosome-negative myeloproliferative neoplasms. This study correlated cytogenetic abnormalities with disease stage and JAK2 status. A total of 17...

2016
Roongrudee Singdong Teerapong Siriboonpiputtana Takol Chareonsirisuthigul Adcharee Kongruang Nittaya Limsuwanachot Tanasan Sirirat Suporn Chuncharunee Budsaba Rerkamnuaychoke

Background: The discovery of somatic acquired mutations of JAK2 (V617F) in Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) has not only improved rational disease classification and prognostication but also brings new understanding insight into the pathogenesis of diseases. Dos...

2016
Madeleine Themanns Kristina M. Mueller Sonja M. Kessler Nicole Golob-Schwarzl Thomas Mohr Doris Kaltenecker Jerome Bourgeais Jamile Paier-Pourani Katrin Friedbichler Doris Schneller Michaela Schlederer Eva Zebedin-Brandl Luigi M. Terracciano Xiaonan Han Lukas Kenner Kay-Uwe Wagner Wolfgang Mikulits Andrey V. Kozlov Markus H. Heim Fabrice Gouilleux Johannes Haybaeck Richard Moriggl

Genetic deletion of the tyrosine kinase JAK2 or the downstream transcription factor STAT5 in liver impairs growth hormone (GH) signalling and thereby promotes fatty liver disease. Hepatic STAT5 deficiency accelerates liver tumourigenesis in presence of high GH levels. To determine whether the upstream kinase JAK2 exerts similar functions, we crossed mice harbouring a hepatocyte-specific deletio...

2012
Wan Du Jie Hong Ying-Chao Wang Yan-Jie Zhang Ping Wang Wen-Yu Su Yan-Wei Lin Rong Lu Wei-Ping Zou Hua Xiong Jing-Yuan Fang

Abnormalities in the JAK2/STAT3 pathway are involved in the pathogenesis of colorectal cancer (CRC), including apoptosis. However, the exact mechanism by which dysregulated JAK2/STAT3 signalling contributes to the apoptosis has not been clarified. To investigate the role of both JAK2 and STAT3 in the mechanism underlying CRC apoptosis, we inhibited JAK2 with AG490 and depleted STAT3 with a smal...

Journal: :Blood 2007
Nicolaus Kröger Anita Badbaran Ernst Holler Joachim Hahn Guido Kobbe Martin Bornhäuser Andreas Reiter Tatjana Zabelina Axel R Zander Boris Fehse

The JAK2-V617F mutation occurs in about 50% of patients with myelofibrosis and might be a reliable marker to monitor residual disease after allogeneic stem cell transplantation. We describe a new, highly sensitive (>or= 0.01%) real-time polymerase chain reaction (PCR) to monitor and quantify V617F-JAK2-positive cells after dose-reduced allogeneic stem cell transplantation. After 22 allogeneic s...

2012
Mamta Gupta Jing Jing Han Mary Stenson Matthew Maurer Linda Wellik Guangzhen Hu Steve Ziesmer Ahmet Dogan Thomas E. Witzig

Cytokines are deregulated in cancers and can contribute to tumor growth. In patients with diffuse large-cell lymphoma (DLBCL), we observed higher levels of JAK/STAT pathway-related serum cytokines (ie, IL-6, IL-10, epidermal growth factor, and IL-2) compared with controls. Of these, only IL-10 activated the JAK2 pathway in lymphoma cells in vitro. Patients with high serum IL-10 had shorter even...

Journal: :Blood 1998
I Dalal E Arpaia H Dadi S Kulkarni J Squire C M Roifman

Members of the Jak family play a critical role in signal transduction mediated by cytokine and hormone receptors. In this study, we report the cloning and characterization of human Jak2. The predicted amino acid sequence shows 91% homology to the described murine Jak2, but with a significant difference in the extreme C-terminal sequence. Using the human cDNA as a probe, we localized the gene fo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید